Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App





Saliva-Based ELISA Tests Measure COVID Neutralizing Antibodies in Multiple Samples at Same Time

By LabMedica International staff writers
Posted on 04 Apr 2022

After any vaccine against the SARS-CoV-2 virus, the body develops neutralizing antibodies which help fight the virus and is thus protective against infections and disease. More...

The degree of protection offered by the vaccine depends on the neutralizing antibodies that are generated by the individual’s immune system. After some time, the neutralizing antibody decreases, and booster doses may be required. Now, two new high-throughput saliva-based ELSIA assays can detect neutralizing activity of samples in response to COVID-19 vaccination.

ReaGene Innovations (Hyderabad, India) has entered into a partnership with Lay Sciences, Inc. (Jupiter, FL, USA) for the development of two patent-pending ELISA and FAST FLOW SPOT diagnostic tests to detect neutralizing activity of samples in response to COVID 19 vaccination. The ELISA diagnostic test can be used in a hospital or pathology lab setting to quantitatively assess multiple samples at the same time. The FAST FLOW SPOT diagnostic test is a single user test that can be used by individuals in a “home” setting. Both diagnostics differ from other tests that measure neutralizing antibodies in blood samples because they only need the individual’s saliva sample. ReaGene will receive royalty payments from Lay Sciences upon the successful launch of the ELISA as well as the FAST FLOW SPOT diagnostic tests.

“Collaboration is important as it requires a concerted team effort to fight and win against a virus like COVID-19 the likes of which we have never seen before. I am also delighted that with the support of Lays Science, we will be able to globally launch these two tests, and which will help us in our fight against COVID-19,” said Dr. Uday Saxena, Scientific Co-Founder of ReaGene Innovations, who led these discoveries.

“These saliva based ELISA and FAST FLOW SPOT diagnostic tests offer yet another line of defense against the onslaught of rapidly evolving SARS-CoV-2 viral variants. These two diagnostic tests are simple and easy-to-use, and this partnership reiterates Lays Sciences’ commitment to fight COVID-19,” added Dr. Satish Chandran, Chief Executive Officer of Lay Science.

Related Links:
ReaGene Innovations
Lay Sciences, Inc. 


Platinum Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
COVID-19 Antigen Test
Epithod616 COVID-19 Ag
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.